Replies to post #106427 on Cytodyn Inc (CYDY)

[daemon57]

This is actually not good news for CYDY either. It will delay further the enrollment to our CD12. I wanted to think we got at least the 195 within 2 weeks but it may be a month or 1.5 months out. Maybe further.

GLTU/A.

[Amatuer17]

This is a good article and helps CYDY. Here is my take from the article

1. The trials seem to be for M2M category and not S2C
2. They are talking about enrolling 400 and 1500 patients - that is a big number
3. Both need the treatment to be started within 3 days of symptoms but in many cases, the diagnosis is taking more than that.

All in all, these trials are going past Sept/Oct timeframe.

LERO M2M trial is done - in one sense it is ahead but it was small so FDA may ask for one more trial - if that happens, then CYDY will compete with these 2 trials and will have delays.

The big news is -Lero is nearing the 195 patient target for S2C (I think 20 patients needed) - the verdict there can be clear Yes or No in terms of deaths. If the results are even just very good (not spectacular) in terms of death reset reduction they can push for EUSA.

Hope they get the sudden rush of 20 patients as they got for M2M